Physician profile
Niraj Parikh
NPI 1295902229
$2,721.02
in general payments reported to CMS, 2019-2025
30 companies · $1,115 in 2025
The $1,115 reported for 2025 was more than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $277 · 2020: $106 · 2021: $135 · 2022: $272 · 2023: $258 · 2024: $557 · 2025: $1,115.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,851 · Education: $79.94.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,850.54 |
| Education | $79.94 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $472.30 | 2019-2025 | Nucala, Trelegy Ellipta, Arexvy |
| Astrazeneca Pharmaceuticals LP | $330.06 | 2019-2025 | Tezspire, Fasenra, Airsupra |
| Inspire Medical Systems, INC. | $274.43 | 2024 | Inspire |
| Regeneron Healthcare Solutions, INC. | $196.38 | 2022-2025 | Dupixent |
| Boehringer Ingelheim Pharmaceuticals, INC. | $177.53 | 2019-2025 | Ofev, Jascayd |
| Grifols USA, LLC | $152.46 | 2019-2024 | Prolastin-C Liquid |
| Resmed Corp | $107.07 | 2023-2025 | |
| Amgen INC. | $97.14 | 2023-2025 | Tezspire |
| Mylan Specialty L.P. | $92.05 | 2019-2024 | Yupelri |
| Genzyme Corporation | $80.77 | 2019-2025 | |
| Lilly USA, LLC | $78.17 | 2025 | Zepbound |
| Harmony Biosciences LLC | $73.98 | 2020-2025 | |
| Jazz Pharmaceuticals INC. | $67.13 | 2020-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $55.21 | 2025 | Glassia |
| United Therapeutics Corporation | $53.88 | 2022-2025 | Tyvaso |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Electromed, INC. | $53.57 | 2022-2025 | Smartvest |
| Insmed, INC. | $43.84 | 2025 | Brinsupri, Arikayce |
| Pfizer INC. | $43.33 | 2025 | |
| Merck Sharp & Dohme LLC | $38.87 | 2019-2024 | Zerbaxa |
| Circassia INC. | $34.40 | 2019-2020 | |
| Intuitive Surgical, INC. | $30.36 | 2021 | |
| Gilead Sciences, INC. | $29.46 | 2021 | |
| Axsome Therapeutics, INC. | $26.21 | 2023 | Sunosi |
| Ani Pharmaceuticals, INC. | $20.32 | 2025 | Purified Cortrophin Gel |
| Viatris Specialty LLC | $19.61 | 2025 | Yupelri |
| Abbvie INC. | $15.92 | 2022 | |
| Boston Scientific Corporation | $15.75 | 2020 | |
| Inari Medical, INC. | $14.95 | 2023 | Flowtriever Catheter, S, Ct Thrombectomy System Kit |
| Verona Pharma, INC. | $13.47 | 2025 | Ohtuvayre |
| Bard Access Systems, INC. | $12.40 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Niraj Parikh listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.